Final logistic regression model for gastric ulcer disease; 11 year cumulative incidence of peptic ulcer disease (PUD). Odds ratios and 95% confidence intervals (CI)*
| Baseline exposure (reference category) | Gastric ulcer | |||
|---|---|---|---|---|
| PUD incidence | Multivariate adjusted* | |||
| % | n | Odds ratio | 95% CI | |
| *All odds ratios are mutually adjusted and adjusted for age, sex, and psychosocial factors. | ||||
| Anti-Hp IgG sero-status | ||||
| (Seronegative) | 0.9 | 1407 | 1.0 | — |
| Borderline | 3.2 | 444 | 2.7 | 1.2;6.6 |
| Seropositive | 0.8 | 526 | 0.7 | 0.2;2.4 |
| Leisure time energy expenditure | ||||
| (Sedentary) | 2.1 | 572 | 1.0 | — |
| Ambulatory | 1.0 | 1268 | 0.4 | 0.1;0.9 |
| Active | 1.1 | 537 | 0.7 | 0.2;2.1 |
| Uspecified gastrointestinal drugs at study entry | ||||
| (Never-infrequent use) | 1.0 | 2029 | 1.0 | — |
| Previous use | 1.6 | 124 | 2.1 | 0.5;10.0 |
| Current use | 3.6 | 222 | 3.0 | 1.1;8.1 |
| Minor tranquilliser use at study entry | ||||
| (Never-infrequent use) | 0.8 | 223 | 1.0 | — |
| Previous use | 3.6 | 28 | 4.0 | 0.5;32.5 |
| Current use | 4.5 | 112 | 3.4 | 1.2;10.0 |
| NSAID use at study entry | ||||
| (Never-infrequent use) | 1.4 | 2079 | 1.0 | — |
| Previous use | 0.5 | 185 | 0.4 | 0.1;2.8 |
| Current use | 1.2 | 80 | 0.7 | 0.1;6.0 |